Cost-effectiveness of extended buprenorphine–naloxone treatment for opioid-dependent youth: data from a randomized trial

July 1, 2012

Conclusions Extended BUP treatment relative to brief detoxification is cost effective in the US health-care system for the outpatient treatment of opioid-dependent youth. (Source: Addiction)

Read the full article →

SUBOXONE (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet [Physicians Total Care, Inc.]

July 1, 2012

Updated Date: Jul 29, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects

July 1, 2012

Abstract: Previous reports have demonstrated greater antinociception following administration of a buprenorphine/naloxone combination compared to buprenorphine alone among healthy volunteers. The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. A repeated-measures, double-blind, cross-over trial was undertaken […]

Read the full article →

Drug Treatment as HIV Prevention: Expanding Treatment Options

July 1, 2012

Abstract  Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use, risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been […]

Read the full article →

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia

July 1, 2012

Conclusions: In Malaysia, BUP and BNX IDU occur among heroin IDUs. The introduction of BNX and withdrawal of BUP may have helped to reduce, but did not eliminate the problems with diversion and abuse. (Source: Drug and Alcohol Dependence)

Read the full article →

Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Approval for Suboxone (buprenorphine and naloxone) Sublingual Film C-III

July 1, 2012

Richmond, VA (31st August 2010) – Reckitt Benckiser Pharmaceuticals Inc. today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) to manufacture and market Suboxone… (Source: Drugs.com – New Drug Approvals)

Read the full article →

MonoSol Rx Announces Reckitt Benckiser FDA Approval Of Suboxone® Sublingual Film For Treatment Of Opioid Dependence

July 1, 2012

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, today announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc (LSE: RB), has received approval from the U.S. Food and Drug Administration (FDA) to market Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual […]

Read the full article →

Opioid Dependence Drug Gets Okay for New Delivery Mode

July 1, 2012

WASHINGTON (MedPage Today) — The FDA has approved a new sublingual film formulation of the opioid dependence treatment combination buprenorphrine/naloxone (Suboxone). (Source: MedPage Today Public Health)

Read the full article →

FDA Approves Sublingual Film Formulation of Buprenorphine/Naloxone

July 1, 2012

Previously only available in sublingual tablet form, buprenorphine/naloxone in the form of a sublingual film will become available in starting in October 2010. Medscape Medical News (Source: Medscape Pharmacist Headlines)

Read the full article →

Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases.

July 1, 2012

CONCLUSIONS: Although codeine can be considered a relatively weak opioid analgesic, it is nevertheless addictive, and the significant morbidity and specific patient characteristics associated with overuse of codeine-ibuprofen analgesics support further awareness, investigation and monitoring of OTC codeine-ibuprofen analgesic use. PMID: 20819050 [PubMed – in process] (Source: Med J Aust)

Read the full article →

← Previous Entries

Next Entries →